Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
telmisartan + verapamil
- Development stage
- Preclinical
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Telmisartan + verapamil** is a combination of two antihypertensive agents: telmisartan, an angiotensin II receptor blocker (ARB), and verapamil, a non-dihydropyridine calcium channel blocker. Telmisartan selectively blocks the angiotensin II type 1 (AT1) receptor, inhibiting the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to a reduction in blood pressure and improvement in metabolic parameters. Verapamil inhibits L-type calcium channels in the heart and vascular smooth muscle, decreasing myocardial contractility and heart rate, and promoting vasodilation. The combination has been investigated for hypertension, and research also supports its use for reducing proteinuria and blood pressure in patients with diabetic nephropathy[2][3][6].
- Other names
- telmisartan + verapamil
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)ABCB1 (P-glycoprotein)PPARG (Peroxisome proliferator-activated receptor gamma)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on telmisartan + verapamil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on telmisartan + verapamil.